Orphan Drugs: Way Too Many, Way Too Expensive.
Sales hit the billion dollar mark as pharmaceutical companies apply creative approaches to increase earnings. For instance, "salami slicing": Dividing diseases into smaller and smaller categories based on genetic and biomarker differences so that the product can achieve the coveted orphan drug status.